What is epitalon?

A peptide modeled on your pineal gland

Epitalon is a synthetic tetrapeptide, four amino acids in the sequence alanine-glutamic acid-aspartic acid-glycine, usually abbreviated AEDG. It is also sold as epithalon. Both names describe the same molecule, and the naming inconsistency between the two, plus between the free base and acetate salt forms it is sold in, turns out to matter later in this story.

The peptide traces back to work by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, who spent decades studying epithalamin, an extract from the pineal gland, the small brain structure that produces melatonin and helps set the sleep-wake cycle. Epitalon was synthesized as a shorter, lab-made stand-in for that extract. The pitch has always been the same: restore what an aging pineal gland stops doing as well on its own.

What the lab research actually shows

The strongest evidence for epitalon is in cell culture. Multiple studies, including a 2025 replication published in Biogerontology, report that epitalon activates telomerase and lengthens telomeres in human cell lines. Telomeres are the protective caps on the ends of chromosomes that shorten as cells divide, and telomere length is one of the more common biomarkers cited in aging research.

Animal work from Khavinson's group adds to that: epitalon-treated mice in some strains showed fewer spontaneous tumors over their lifespan, and a primate study reported the peptide restored more normal evening melatonin production and cortisol rhythms in older monkeys. None of that is a completed human clinical trial showing a therapeutic benefit. It is preclinical and mechanistic evidence, the same category of data that underlies a lot of the compounds in our peptide stacks guide, and it comes almost entirely from a small number of Russian labs rather than being independently confirmed at scale.

The FDA review was about insomnia, not anti-aging

This is the part most coverage gets wrong. When the FDA posted its briefing document for epitalon ahead of the July 23-24, 2026 Pharmacy Compounding Advisory Committee hearing, the headline in most outlets was some version of "anti-aging peptide under FDA review." The actual nomination FDA evaluated proposed epitalon as a treatment for insomnia.

FDA staff noted that the nomination packages also referenced anti-aging, longevity, telomere lengthening, skin health, and several other uses, but said none of those came with enough supporting information for the agency to evaluate them at all under the 503A nomination process. So the entire effectiveness and safety review, the one that produces the headline "FDA reviews epitalon," turned on a single question: does the evidence support using it for insomnia. That is a narrower and, it turns out, weaker case than the anti-aging framing most sites lead with.

The one human study FDA found

FDA staff identified a single relevant human study: Ivko et al. 2021, a randomized, placebo-controlled trial of 75 women aged 40 to 50 who worked night shifts. Forty of them had lower-than-expected levels of a melatonin metabolite in their urine. Those 40 were split into two groups and given either a placebo spray or a sublingual epitalon spray, twice daily for 20 days.

The epitalon group's melatonin metabolite levels rose 1.7-fold and returned to an age-appropriate range; the placebo group did not change. Researchers also reported that 83% of the epitalon group showed improved "psycho-emotional and general physical condition," against 25% on placebo, though the paper did not describe how that was measured. What the study did not do is measure sleep itself: no sleep latency, no time awake, none of the outcomes a real insomnia trial would need. It also used a sublingual spray, not the subcutaneous injection most epitalon sold online is meant for. FDA staff concluded that gap alone is enough to sink the effectiveness case, separate from the study's small size and short duration.

Why FDA flagged a cancer risk instead of a benefit

The detail most likely to surprise epitalon users: FDA staff treated the telomerase research, the same finding sold as epitalon's biggest selling point, as a safety concern rather than a benefit. Telomerase activation lengthens telomeres, and longer telomeres are generally associated with a higher risk of cancer, not a lower one. FDA said the available mouse studies, which used a single fixed dose, tested only female mice, and ran for a short exposure window, were too limited to rule out that risk.

Combine that with zero identified human safety data for the injectable form, plus concerns about immunogenicity from peptide aggregation and impurities common to compounded peptide injections, and FDA staff landed on the same conclusion they reached for BPC-157 and TB-500: the safety case for epitalon in humans has not been made.

Where the process stands right now

Epitalon is one of seven peptides FDA staff reviewed in this round, alongside MOTS-c, BPC-157, and TB-500. The advisory committee still votes at the July 23-24 hearing, and the FDA makes its own final call afterward with no set timeline. A staff conclusion this specific, the wrong indication reviewed, one weak human study, an unaddressed cancer-risk question, makes a reversal at the hearing unlikely for epitalon specifically.

What this means if you are considering epitalon today

Nothing about your ability to buy epitalon changes this week regardless of how the hearing goes. It was never FDA-approved, and a 503A Bulks List decision only affects whether licensed compounding pharmacies can fill a physician-written prescription under formal FDA authorization. The online research-chemical market that sells most epitalon today operates outside that system and is not touched by this process either way.

The more useful takeaway is about the evidence itself. The telomere and melatonin research is real, published, and worth taking seriously as early science. It is not the same thing as a peptide with demonstrated human benefit and a known safety profile, and FDA staff's own read is that the strongest mechanistic claim behind epitalon carries a plausible downside that has not been ruled out. For where epitalon fits alongside the other peptides in this same regulatory moment, see our full preview of the July 23-24 hearing.